Last reviewed · How we verify
OmegaD
OmegaD is a small molecule that modulates the activity of a specific enzyme involved in lipid metabolism.
OmegaD is a small molecule that modulates the activity of a specific enzyme involved in lipid metabolism. Used for Hypercholesterolemia, Mixed dyslipidemia.
At a glance
| Generic name | OmegaD |
|---|---|
| Sponsor | OmegaD LLC |
| Drug class | Lipid-lowering agent |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By inhibiting this enzyme, OmegaD reduces the production of certain lipids in the body, which can help lower cholesterol levels and reduce the risk of cardiovascular events.
Approved indications
- Hypercholesterolemia
- Mixed dyslipidemia
Common side effects
- Musculoskeletal pain
- Gastrointestinal upset
- Headache
Key clinical trials
- Phase 3 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease (PHASE3)
- Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease (PHASE3)
- OmegAD (Omega-3 and Alzheimer's Disease) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OmegaD CI brief — competitive landscape report
- OmegaD updates RSS · CI watch RSS
- OmegaD LLC portfolio CI